Article
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
HIV medicine - 1 Nov 2009
Hill A, Marcelin A-G, Calvez V
Abstract excerpt
BACKGROUND: Genotypic algorithms used to predict the clinical efficacy of lopinavir/ritonavir (LPV/r) have included a range of mutation lists and efficacy endpoints. Normally, HIV clinical trials are powered to detect a difference between treatment arms of 10-12% for the endpoint of viral load su...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.